Salome Mekhuzla: Representing WFH’s Voice in Front of WHO Leadership and National Governments
Salome Mekhuzla, Director of Global Development at the World Federation of Hemophilia, shared World Federation of Hemophilia’s post on LinkedIn, adding:
“Read the WFH open letter to the WHO Director-General in support for the draft resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders here!
This landmark resolution is scheduled to be discussed at the 158th session of the WHO Executive Board, February 2nd, tentatively in the afternoon central european time, so morning hours for those in EST time zone. The WFH will be participating at this session and we will deliver a statement to represent our global community’s voice in front of WHO leadership and national governments!
Keep an eye on our social media posts on Monday, as we will share a web link for anyone interested to follow this discussion live.”
Quoting World Federation of Hemophilia’s post:
“The World Federation of Hemophilia has formally presented a letter to the WHO Director-General, urging support for a World Health Assembly resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.
This global call highlights the ongoing gaps in diagnosis, treatment, and care, and the urgent need for coordinated action so access to care no longer depends on where someone lives.
The draft resolution is tabled for discussion at the 158th Session of the WHO Executive Board (EB158) in Geneva during February 2 to 7, 2026. The WFH commands leadership of WHO Member States in driving this resolution adoption process: Armenia as lead Member States, and co-sponsored by Bosnia & Herzegovina, Egypt, Georgia, Iraq, Latvia, Malta, Morocco, Nepal, Paraguay, Spain, Sri Lanka and Togo. The WFH also thanks all member and partner organizations who have joined the WFH’s Global Call for Health Equity for Bleeding Disorders in support of the landmark resolution.
More posts featuring Salome Mekhuzla.
-
Apr 12, 2026, 14:27Moustafa Abdou: Paroxysmal Nocturnal Hemoglobinuria From a Rare Disease to a Treatable Condition
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
-
Apr 12, 2026, 13:53Alan Nurden: A Contemporary Update on the Pathogenesis of Inherited Platelet Dysfunction
-
Apr 12, 2026, 13:47Kalyan Roy: Visual Inspection of Blood Bags and Blood Products
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation